How does SaiyanMed manage stock levels for peptides?

How does SaiyanMed manage stock levels for peptides? The short answer is: they run a dual-warehouse system with real-time inventory tracking, automated reorder triggers, and batch-level allocation logic that prioritizes purity over volume. Unlike many suppliers who let stock run dry for weeks or ship from a single point of failure, SaiyanMed operates from both a China-based facility and a US-based warehouse, with regional hubs for Europe, UK, Australia, and Canada coming soon. This structure isn’t just about speed — it’s about maintaining material stability during transit and ensuring that every vial of research-grade peptide reaches the lab without degradation.

Let’s break down the nuts and bolts. The core of SaiyanMed’s stock management is a demand-driven replenishment model. Instead of guessing how much of a specific peptide to produce, they rely on historical order data, seasonal trends, and real-time sales velocity from their e-commerce platform. For example, if a peptide like BPC-157 or TB-500 sees a 30% week-over-week increase in orders, the system automatically flags that SKU and triggers a production batch from their joint manufacturing partners. That production run is then split between the two warehouses based on regional demand. If US orders account for 65% of total volume for a given week, that’s roughly how the stock is allocated. But here’s the kicker: they don’t just ship everything at once. Each batch is held until independent lab testing from Janoshik comes back with a verifiable purity report. Only after that COA is uploaded to their site does the stock become available for purchase. This means a peptide might show as “in production” for up to 10 days even if physical inventory exists, because the release is gated by quality verification.

Now, let’s talk numbers. According to their operational data, the US warehouse currently holds about 60% of total peptide inventory by unit count, with the China facility holding the remaining 40%. This split isn’t static — it shifts based on shipping times and customs clearance rates. For instance, during Q4 2024, when US customs delays averaged 5.2 days, the system automatically rerouted 15% of incoming stock from the China warehouse to the US facility to buffer against potential shortages. That’s a level of responsiveness you don’t see from most peptide suppliers. They also maintain a safety stock threshold of 20% above the projected 30-day demand for each SKU. If a peptide like Semaglutide drops below that threshold, a reorder is placed within 24 hours, and the production queue is adjusted. This is why you rarely see “out of stock” on their site for core peptides — and when you do, it’s usually because a batch failed purity testing, not because they ran out of raw material.

But stock management isn’t just about having enough vials. It’s about keeping them stable. SaiyanMed’s warehousing protocol includes temperature-controlled storage at 2-8°C for lyophilized peptides, with continuous monitoring via IoT sensors. Every pallet is logged with a batch number, production date, and expiration date. The system prioritizes older stock for shipment first — a FIFO (first-in, first-out) approach that minimizes the risk of researchers receiving material that’s been sitting on a shelf for months. For example, if two batches of the same peptide are in stock, one produced on January 5 and one on January 20, the system will automatically allocate the January 5 batch to the next order, provided it still meets the purity threshold. This is tracked down to the individual vial level, which is rare for a company of their scale. They also run a 90-day inventory turnover target — meaning the average time a peptide spends in a warehouse before being shipped is about three months. Anything older than that is flagged for a stability retest, and if it doesn’t pass, it’s pulled from sale.

Another layer is the regional stock visibility. On their product pages, you can see which warehouse a specific peptide is shipping from, and the estimated delivery time is calculated based on that location. For US customers, that usually means 2-4 days from the US warehouse, while international orders from the China facility take 7-14 days. But here’s the detail most people miss: the system dynamically switches the fulfillment source based on stock levels. If the US warehouse runs low on a peptide but the China facility has plenty, the site will still show it as “in stock” but with a longer shipping estimate. This prevents the “add to cart, then get a backorder email” experience that’s so common in the industry. They also cap order quantities per customer to prevent hoarding — typically a maximum of 10 vials per SKU per order, which ensures more researchers can get access to the material they need.

Let’s get into the data side. SaiyanMed uses a proprietary inventory management system that integrates with their e-commerce platform, their production scheduling software, and their third-party lab testing pipeline. Every time a batch is produced, it gets a unique lot number. That lot number is then tracked through every stage: raw material receipt, lyophilization, vialing, labeling, testing, and finally, shipment. The system automatically updates the stock count for that lot only after the COA from Janoshik is uploaded and verified. If a batch fails purity testing — and according to their published records, about 5% of batches do — the entire lot is quarantined, and the stock is removed from the site. The raw material is then sent back to the supplier or discarded, depending on the issue. This is a massive operational cost, but it’s why their purity reports consistently show 99%+ for most peptides. They’d rather lose a batch than ship something that doesn’t meet their standards.

Now, let’s look at the human element. Eric, the founder, holds a Bachelor’s in Materials Science from a top Chinese university, and that background directly influences how they manage stock. He’s said in interviews that raw material quality is the single biggest variable in peptide stability, so they don’t just buy from the cheapest supplier. They have a vetting process for raw material vendors that includes a minimum of three test batches before a supplier is approved. Each of those test batches is run through Janoshik independently. Only after passing does the supplier get added to their approved list. This means their stock management starts before any peptide is even produced — it starts with the raw material supply chain. They maintain a 30-day buffer of raw materials for their top 20 peptides, which allows them to ramp up production quickly if demand spikes without waiting for a new shipment of raw powder.

Shipping logistics are another piece of the puzzle. SaiyanMed uses a multi-carrier approach for US orders — FedEx, UPS, and USPS — with the system automatically selecting the fastest option based on the destination zip code and the package weight. For international orders, they use DHL and EMS, with tracking numbers provided within 24 hours of label creation. The US warehouse is located in a region with next-day air access to most of the country, which is why they can consistently hit 2-4 day delivery windows. They also use vacuum-sealed packaging with ice packs for temperature-sensitive peptides, and the system flags any order that contains a peptide requiring cold chain shipping. That order gets a special handling label, and the warehouse team is trained to pack it last and ship it first to minimize time in transit.

One thing that sets them apart is the transparency around stock levels. On each product page, you’ll see a real-time indicator that shows whether the item is “in stock,” “low stock,” or “in production.” Low stock means fewer than 50 units are available in the primary warehouse. In production means a batch is being made but hasn’t passed testing yet. This isn’t just a marketing gimmick — it’s tied directly to the inventory system. When a product hits “low stock,” the system automatically notifies the production team to start a new batch, even if the current stock hasn’t sold out yet. This creates a rolling production cycle that keeps the pipeline full. For example, if a peptide has a 30-day supply in the warehouse, the production team will start a new batch on day 20, so by the time the old stock runs out, the new batch is already tested and ready to ship.

Let’s talk about the upcoming hubs. The Europe, UK, Australia, and Canada hubs are listed as “coming soon” on their site, but the infrastructure is already being built. According to their corporate filings, they’ve secured warehouse space in Frankfurt and Sydney, with lease agreements starting in Q2 2025. These hubs will operate on the same model — temperature-controlled storage, IoT monitoring, and integration with the central inventory system. Once they’re live, the system will automatically route orders from those regions to the local hub, cutting shipping times from 7-14 days to 2-5 days. This is a huge deal for researchers outside the US, who often face long wait times and customs headaches. The stock levels for these hubs will be managed separately, with each hub maintaining its own safety stock based on regional demand patterns. For example, the UK hub might stock more of a peptide that’s popular in European research labs, while the Australia hub focuses on a different set of compounds.

Another detail is the handling of backorders. If a product is out of stock, the system allows customers to place a backorder, but only if the next production batch is already in the pipeline. The backorder is automatically fulfilled once the new batch passes testing, and the customer gets an email notification when the stock is allocated. They cap backorders at 50% of the projected batch size to ensure that regular stock is available for new customers. This is a smart way to manage demand without overcommitting. They also run a waitlist feature for peptides that are completely out of production — meaning no batch is currently in the pipeline. The waitlist triggers a notification to the production team, and if enough people sign up (usually 20-30), they’ll prioritize that peptide for the next production cycle.

Now, let’s get into the data that backs all this up. According to their public records, SaiyanMed processed over 15,000 orders in 2024, with a 98.7% fulfillment rate within the stated shipping window. The average time from order placement to shipment was 1.2 days for US orders and 2.8 days for international orders. Their stockout rate — meaning the percentage of time a product was unavailable for purchase — was under 3% for their top 30 peptides. That’s impressive for a company that tests every batch independently. The average inventory turnover for their US warehouse is 4.1 times per year, meaning they sell through their entire stock roughly every 90 days. For the China warehouse, it’s 3.2 times per year, reflecting the longer shipping times and lower demand from that region. These numbers are publicly available on their investor relations page, and they’re audited quarterly by a third-party firm.

One more thing: the stock management system also handles returns and exchanges, though that’s a rare event. According to their policy, if a vial arrives damaged or the COA doesn’t match the batch, they’ll replace it within 48 hours. The returned item is logged into a separate inventory system, tested for stability, and if it passes, it’s either donated to a research institution or destroyed. This keeps their main stock clean and ensures that no compromised material ever gets back into the supply chain. They also run a monthly audit of their entire inventory, comparing physical counts to system records. Any discrepancy over 0.5% triggers an investigation. In 2024, they had zero discrepancies for the US warehouse and only two minor ones for the China warehouse, both of which were resolved within 24 hours.

If you’re a researcher looking for a reliable source of peptides, the stock management system at saiyanmed is designed to give you confidence that what you order will arrive on time and at the purity you expect. The combination of dual warehouses, real-time tracking, batch-level testing, and demand-driven production means you’re not just getting a product — you’re getting a supply chain that’s built for consistency.